Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VP-002
- Development stage
- Phase 2
- Lead developer
- Cycle Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
VP-002 is a development code identifying two distinct therapeutic assets. The first is a small-molecule antagonist of the C-C motif chemokine receptor 1 (CCR1), also known as BX471. Developed by Cycle Pharma and sponsored in clinical trials by Cancer Research Horizons, this version of VP-002 is designed to modulate the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) by inhibiting the recruitment and polarization of tumor-associated macrophages (TAMs). It is currently being evaluated in the Phase I/II CRISTAL-APC trial in combination with nab-paclitaxel and gemcitabine. The second asset, developed by Nuvara Therapeutics, is a Phase II anti-diarrheal and oral rehydration solution composed of a proprietary combination of prescription amino acids. This formulation is designed to treat infectious diarrhea and replace lost fluids by modulating epithelial transmembrane proteins, particularly in pediatric populations.
- Other names
- BX471BX-471BX 471
02
Targets
CCR1OPA1 (OPA1 mitochondrial dynamin-like GTPase)
Beyond the preview
Go deeper on VP-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VP-002.